American Journal of Kidney Diseases最新文献

筛选
英文 中文
Making IMPACT (Improving Methodology for Proteinuria and Albuminuria measurement in Clinics and Trials): A Report of the 2025 Proteinuria-Albuminuria Workshop Sponsored by the National Kidney Foundation. Making IMPACT(改进临床和试验中蛋白尿和白蛋白尿测量方法):由国家肾脏基金会主办的2025年蛋白尿-白蛋白尿研讨会报告。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-14 DOI: 10.1053/j.ajkd.2026.10.004
Hiddo J L Heerspink, Lesley Inker, Niels Jongs, Sean J Barbour, Jonathan Barratt, J M Beernink, Morgan Grams, Bengt Fellstrom, Kei Fukami, William G Herrington, W Greg Miller, Peter Rossing, Joseph Vassalotti, Kerry Willis, Ron Gansevoort
{"title":"Making IMPACT (Improving Methodology for Proteinuria and Albuminuria measurement in Clinics and Trials): A Report of the 2025 Proteinuria-Albuminuria Workshop Sponsored by the National Kidney Foundation.","authors":"Hiddo J L Heerspink, Lesley Inker, Niels Jongs, Sean J Barbour, Jonathan Barratt, J M Beernink, Morgan Grams, Bengt Fellstrom, Kei Fukami, William G Herrington, W Greg Miller, Peter Rossing, Joseph Vassalotti, Kerry Willis, Ron Gansevoort","doi":"10.1053/j.ajkd.2026.10.004","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.10.004","url":null,"abstract":"<p><p>Glomerular damage is traditionally assessed by measuring urinary protein loss. While both the urinary albumin-creatinine ratio (UACR) and protein-creatinine ratio (UPCR) are used in clinical practice via 24-hour or spot urine samples, a more uniform approach to the assessment of urinary proteins and guidance when and how to assess urinary proteins would facilitate the diagnosis and monitoring of CKD. The United States National Kidney Foundation sponsored a scientific workshop to define optimal methods for the measurement of urinary proteins in April 2025. Based on existing literature, prospective studies and meta-analyses, workshop participants concluded that in general the measurement of urinary albumin is preferred over measurement of total urinary protein for several reasons. Firstly, urinary albumin assays are expected to be internationally standardized beginning in 2027, allowing optimal comparability within laboratories over time and across laboratories. Secondly, optimal pre-analytical handling of urine samples are well documented for urinary albumin unlike protein. Thirdly, urinary albumin concentration shows a moderately stronger association with clinical outcomes compared to urinary total protein, particularly in high-risk individuals. Thus, measurement of urinary albumin concentration should in general be preferred when determining the urinary excretion of proteins in future clinical practice and trials.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patterns of Anticoagulant Use in Older Medicare Beneficiaries with Advanced CKD and Newly Diagnosed Atrial Fibrillation. 老年医疗保险受益人晚期CKD和新诊断房颤的抗凝使用模式。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-11 DOI: 10.1053/j.ajkd.2026.07.019
Sai Liu, Wolfgang C Winkelmayer, Maria E Montez-Rath, Tara I Chang
{"title":"Patterns of Anticoagulant Use in Older Medicare Beneficiaries with Advanced CKD and Newly Diagnosed Atrial Fibrillation.","authors":"Sai Liu, Wolfgang C Winkelmayer, Maria E Montez-Rath, Tara I Chang","doi":"10.1053/j.ajkd.2026.07.019","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.019","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Burden of Occult Cerebrovascular Disease in CKD: A Scoping Review. 慢性肾病隐匿性脑血管疾病的负担:范围综述。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-11 DOI: 10.1053/j.ajkd.2026.07.018
Maryam Vasaghi-Gharamaleki, Seyed Behnam Jazayeri, Abhiram Pillai, Kirsten L Johansen, Anne M Murray, Sanaz Sedaghat, Behnam Sabayan
{"title":"The Burden of Occult Cerebrovascular Disease in CKD: A Scoping Review.","authors":"Maryam Vasaghi-Gharamaleki, Seyed Behnam Jazayeri, Abhiram Pillai, Kirsten L Johansen, Anne M Murray, Sanaz Sedaghat, Behnam Sabayan","doi":"10.1053/j.ajkd.2026.07.018","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.018","url":null,"abstract":"<p><strong>Rationale & objective: </strong>Occult cerebrovascular diseases (OCCD) including extracranial and intracranial atherosclerotic disease (ECAD and ICAD) and cerebral small vessel disease (CSVD) are asymptomatic cerebrovascular abnormalities associated with future risk of stroke and dementia. Although chronic kidney disease (CKD) is strongly associated with adverse brain health outcomes, the breadth of evidence regarding OCCD in people with CKD has not been comprehensively characterized. This scoping review summarizes the available literature on OCCD among adults with CKD without clinically overt cerebrovascular disease.</p><p><strong>Sources of evidence: </strong>PubMed, EMBASE, Web of Science, and Scopus were searched for studies published between January 2000 and July 2025.</p><p><strong>Eligibility criteria: </strong>Peer-reviewed studies reporting the frequency or characteristics of OCCD manifestations in adults with CKD without a known history of stroke or transient ischemic attack.</p><p><strong>Charting methods: </strong>Two reviewers independently screened studies and extracted data on study characteristics, CKD definitions, neuroimaging modalities, and reported OCCD findings. Methodological quality was assessed using a modified Newcastle-Ottawa Scale.</p><p><strong>Results: </strong>Forty-six studies comprising 5,153 participants with CKD were included. Study populations varied substantially with respect to CKD stage, dialysis status, study design, and imaging methodology. Two studies evaluating ICAD reported moderate-to-severe intracranial stenosis in approximately one-quarter of participants with CKD. Across studies evaluating ECAD, the frequency of significant extracranial carotid stenosis ranged from approximately 3% in patients with non-dialysis-dependent CKD to 28% among patients receiving dialysis. Thirty-eight studies evaluated manifestations of CSVD, including cerebral microbleeds, silent cerebral infarctions, white matter hyperintensities, and enlarged perivascular spaces. Several studies suggested a greater burden of CSVD manifestations among patients with advanced CKD or dialysis dependence. Reported frequencies varied considerably across studies.</p><p><strong>Limitations: </strong>Considerable heterogeneity in study populations, CKD definitions, imaging protocols, and outcome ascertainment methods limited direct comparison across studies.</p><p><strong>Conclusions: </strong>Occult cerebrovascular abnormalities are frequently reported across diverse CKD populations, particularly among patients with advanced kidney disease. Variation in the prevalence of abnormalities may reflect differences in CKD severity, participant characteristics, neuroimaging protocols, and outcome definitions. These findings highlight the need for standardized neuroimaging approaches and prospective studies to better characterize the clinical implications of OCCD in CKD.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dialysis-Related Ethics Consultations Among Hospitalized Patients: Patterns and Outcomes at an Urban Academic Center. 住院患者透析相关伦理咨询:城市学术中心的模式和结果
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-11 DOI: 10.1053/j.ajkd.2026.08.010
Regina M Longley, Cecilia Katzenstein, Isabelle Band, Dinushika Mohottige, Krishna Chokshi
{"title":"Dialysis-Related Ethics Consultations Among Hospitalized Patients: Patterns and Outcomes at an Urban Academic Center.","authors":"Regina M Longley, Cecilia Katzenstein, Isabelle Band, Dinushika Mohottige, Krishna Chokshi","doi":"10.1053/j.ajkd.2026.08.010","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.08.010","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rituximab in IgA Nephropathy: The RITA Multicenter Randomized Trial. 利妥昔单抗治疗IgA肾病:RITA多中心随机试验
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-07 DOI: 10.1053/j.ajkd.2026.07.017
Yan Ouyang, Hong Ren, Weiming Wang, Na Liu, Beiyan Bao, Hua Li, Xiaoling Xiong, Jian Li, Duolao Wang, Qinjie Weng, Chaohui Wang, Jingyuan Xie, Nan Chen
{"title":"Rituximab in IgA Nephropathy: The RITA Multicenter Randomized Trial.","authors":"Yan Ouyang, Hong Ren, Weiming Wang, Na Liu, Beiyan Bao, Hua Li, Xiaoling Xiong, Jian Li, Duolao Wang, Qinjie Weng, Chaohui Wang, Jingyuan Xie, Nan Chen","doi":"10.1053/j.ajkd.2026.07.017","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.017","url":null,"abstract":"<p><strong>Rationale & objective: </strong>B-cell dysregulation contributes to IgA nephropathy (IgAN). Rituximab (RTX) targets CD20-positive B cells, but its efficacy in adults with IgAN receiving stable renin-angiotensin system inhibitor (RASI) therapy remains uncertain. This study sought to evaluate the efficacy and safety of RTX combined with RASI therapy compared with RASI therapy alone.</p><p><strong>Study design: </strong>Multicenter, randomized, controlled trial.</p><p><strong>Setting & participants: </strong>Chinese adults with biopsy-proven IgAN across 10 centers, with 24-hour urine total protein (UTP) >1 g/day despite ≥3 months RASI therapy, and blood pressure <130/80 mmHg.</p><p><strong>Interventions: </strong>RTX plus RASI versus RASI alone for 12 months OUTCOMES: Primary: 24-hour UTP change at month 12. Secondary continuous: changes in 24-hour UTP at month 6 and in eGFR and serum Gd-IgA1 at month 12. Secondary categorical: ≥50% reduction in 24-hour UTP at months 6 and 12, ≥50% eGFR decline or doubling of serum creatinine, and ESKD.</p><p><strong>Safety: </strong>adverse events, serious adverse events, and infections. Exploratory analyses examined outcomes through month 24.</p><p><strong>Results: </strong>Among the 106 participants randomized (53 per group), 24-hour UTP change at 12 months was similar between groups (adjusted GMR, 1.05; 95% CI, 0.80-1.36). Median change of 24-hour UTP was -0.21 g/day for RTX and -0.26 g/day for RASI. No statistically significant differences were observed in eGFR (adjusted mean difference, 3.80 mL/min/1.73 m<sup>2</sup>; 95% CI, -0.47 to 8.06), Gd-IgA1 (adjusted GMR, 1.04; 95% CI, 0.87-1.24), or the proportion achieving a ≥50% reduction in 24-hour UTP (15.1% vs 20.8%). Adverse events occurred at similar rates between two groups; no events of ≥50% eGFR decline, doubling of serum creatinine, or ESKD occurred during the 12-month treatment period. These findings were consistent with analyses that included outcome data through month 24.</p><p><strong>Limitations: </strong>The follow-up period was relatively short, and only Asian patients were enrolled.</p><p><strong>Conclusions: </strong>No additional reduction in proteinuria or preservation of kidney function was observed with the addition of RTX to optimized RASI-based therapy in patients with IgAN.</p><p><strong>Funding: </strong>Grants from government (National Key Research and Development Program, Major International [Regional] Joint Research Program of China, National Natural Science Foundation of China, National Facility for Translational Medicine [Shanghai], Shanghai 'Rising Stars of Medical Talent' Youth Development Program), academic (Shanghai Shenkang Hospital Development Center), and non-profit (International Society of Nephrology) sources.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149369820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Living Kidney Donation for Symptomatic Nutcracker Syndrome: A Multicenter Experience Using Kidney Paired Exchange. 治疗性活肾捐赠治疗胡桃夹子综合征:多中心肾脏配对交换的经验。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-05 DOI: 10.1053/j.ajkd.2026.06.039
Abraham J Matar, Clark Kensinger, Alvin G Thomas, Kenneth Chavin, Raja Kandaswamy
{"title":"Therapeutic Living Kidney Donation for Symptomatic Nutcracker Syndrome: A Multicenter Experience Using Kidney Paired Exchange.","authors":"Abraham J Matar, Clark Kensinger, Alvin G Thomas, Kenneth Chavin, Raja Kandaswamy","doi":"10.1053/j.ajkd.2026.06.039","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.039","url":null,"abstract":"<p><p>Therapeutic living kidney donation (TLKD), in which a nephrectomy is performed as definitive treatment for a donor condition, remains uncommon. This multicenter study reports outcomes of seven patients from three centers with symptomatic nutcracker syndrome (NCS) who underwent TLKD through kidney paired exchange between 2022-2024. Among the seven donors, the majority were female (n = 6). Median age was 38 y (range: 23-55 y), and median BMI was 22.9 (range: 19.0-32.6). Nephrectomies were performed via laparoscopic (n = 2), laparoscopic hand-assisted (n = 4), or open (n = 1) technique. All kidneys were transplanted successfully through national paired kidney exchange. Donor creatinine levels increased from a mean of 0.71 mg/dL preoperatively to 1.08 mg/dL at six months. All donors reported symptom relief, with no perioperative complications. Recipient outcomes showed stable renal function, with mean creatinine of 1.1 mg/dL at 6 months and 1.2 mg/dL at 1 year. TLKD offers symptom resolution for appropriately selected donors and access to transplantation for recipients. Further longitudinal data will clarify patient selection and long-term outcomes, but these data suggest TLKD in refractory NCS is feasible.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
B-Cell Maturation Antigen T-Cell Engager Therapy in a Patient With Refractory Plasma Cell Clonal Cryoglobulinemia Unmasked by RNA-Based Immunoglobulin Sequencing. 基于rna的免疫球蛋白测序揭示难治性浆细胞克隆性冷球蛋白血症患者的b细胞成熟抗原t细胞参与治疗。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-03 DOI: 10.1053/j.ajkd.2026.06.038
Bénédicte Piron, Jérôme Han Yee Yu, Hélène Caillon, Virginie Pascal, Benoit Tessoulin, Cyrille Touzeau, Yannick Le Bris, Karine Renaudin, Nicolas Blin, Simon Ville
{"title":"B-Cell Maturation Antigen T-Cell Engager Therapy in a Patient With Refractory Plasma Cell Clonal Cryoglobulinemia Unmasked by RNA-Based Immunoglobulin Sequencing.","authors":"Bénédicte Piron, Jérôme Han Yee Yu, Hélène Caillon, Virginie Pascal, Benoit Tessoulin, Cyrille Touzeau, Yannick Le Bris, Karine Renaudin, Nicolas Blin, Simon Ville","doi":"10.1053/j.ajkd.2026.06.038","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.038","url":null,"abstract":"<p><p>Treatment of type I cryoglobulinemic glomerulonephritis depends on identifying the monoclonal clone responsible for cryoglobulin secretion. We report the case of a woman in whom the culprit clone proved exceptionally difficult to detect, making treatment guidance highly uncertain. Using the RACE RepSeq technique combined with innovative bone marrow cell sorting, and later through direct visualization within the kidney, we identified a likely plasma cell clone responsible for the cryoglobulin. Despite targeted interventions, the disease remained refractory to conventional therapies, teclistamab, a bispecific T-cell-engaging antibody redirecting T cells against plasma cells, achieved efficacy. Finally, residual disease monitoring was possible through a novel targeted mass spectrometry approach (MALDI-TOF MS), sensitive enough to visualize the cryoglobulin M-protein. This case highlights the challenges of detecting elusive monoclonal clones in many monoclonal gammopathies of renal significance, illustrates the potential of advanced diagnostic tools, and underscores the promise of T-cell-redirecting therapies in refractory cryoglobulinemic glomerulonephritis.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD. 蛋白尿指导下CKD风险分层和治疗决策的方法。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-02 DOI: 10.1053/j.ajkd.2026.06.033
Ishfaq Rashid, Hiddo J L Heerspink, Lesley A Inker
{"title":"An Albuminuria Guided Approach to Risk Stratification and Therapeutic Decision-Making in CKD.","authors":"Ishfaq Rashid, Hiddo J L Heerspink, Lesley A Inker","doi":"10.1053/j.ajkd.2026.06.033","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.033","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a global public health challenge, yet therapeutic evaluation and regulatory acceptance are constrained by reliance on late clinical endpoints such as kidney failure. Albuminuria, assessed as urine albumin-to-creatinine ratio (UACR) reflects glomerular and systemic vascular injury and responds rapidly to treatment. Epidemiologic evidence demonstrates a continuous, graded association between both baseline and changes in UACR and subsequent risk for kidney failure, cardiovascular events, and mortality. Trial level analyses demonstrate that treatment effects on change in UACR is also associated with long-term treatment benefit on CKD progression across drug classes and disease populations. Meta-analysis indicates that a treatment benefit of ≥30% decline in UACR is associated with approximately a 20% treatment benefit on CKD progression, supporting its use as a clinically meaningful surrogate endpoint. Residual albuminuria during treatment identifies patients at persistently high risk and provides a rationale for therapy intensification. Recent studies demonstrate that combination therapies can achieve substantial additional reductions in UACR, in selected settings exceeding 50%. This review synthesizes biological, epidemiologic, and clinical trial evidence supporting albuminuria-guided risk stratification and a treat-to-target approach using serial UACR monitoring to personalize CKD care, while improving clinician understanding of albuminuria changes as markers of therapeutic response.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proliferative Glomerulonephritis With Monotypic Immunoglobulin Deposits of IgG1 Subclass: A Case Series. 增殖性肾小球肾炎伴单型免疫球蛋白沉积IgG1亚类:一个病例系列
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-02 DOI: 10.1053/j.ajkd.2026.07.016
Lihong Bu, Lisa E Vaughan, Samar M Said, Yi Zhu, Chuan Chen, Mohammed Abdalla, Alessia Buglioni, Pingchuan Zhang, Loren Herrera Hernandez, Sanjeev Sethi, Christopher P Larsen, Nelson Leung, Samih H Nasr
{"title":"Proliferative Glomerulonephritis With Monotypic Immunoglobulin Deposits of IgG1 Subclass: A Case Series.","authors":"Lihong Bu, Lisa E Vaughan, Samar M Said, Yi Zhu, Chuan Chen, Mohammed Abdalla, Alessia Buglioni, Pingchuan Zhang, Loren Herrera Hernandez, Sanjeev Sethi, Christopher P Larsen, Nelson Leung, Samih H Nasr","doi":"10.1053/j.ajkd.2026.07.016","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.07.016","url":null,"abstract":"<p><strong>Rationale & objective: </strong>Most cases of proliferative glomerulonephritis with monotypic immunoglobulin deposits (PGNMID) are associated with IgG3. The characteristics of IgG1 deposits within PGNMID have not been well defined and are the focus of this study.</p><p><strong>Study design: </strong>Retrospective case series.</p><p><strong>Setting & participants: </strong>Forty-six PGNMID cases with granular monotypic IgG1 deposits (PGNMID-IgG1) identified in nephropathology archives.</p><p><strong>Findings: </strong>57% of cases were male and 78% had hematuria. The median age was 57 years, the median proteinuria level was 4.8 g/day, and the median eGFR level was 52 mL/min/1.73 m<sup>2</sup>. Hypocomplementemia was uncommon (12%). Kidney biopsy revealed MPGN (54%) or mesangial proliferative GN (33%), with membranous features in nearly half (43%). A nephropathic clone or monoclonal Ig (mIg) was detected in 19 of 42 patients with PGNMID-IgG1 who underwent evaluation, including 10 with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Among patients >50 years, the detection rate was 72% (18/25) vs. 6% (1/17) among younger patients. SPEP/SIF detected the nephropathic mIg in 13 of 40, and bone marrow biopsy done in 25 detected clonal B-cells in eight and clonal plasma cells in two patients. Follow-up (median 27 months) was available for 37 patients. Ten (83%) of 12 patients with an identifiable clone or mIg responded to clone-targeted (anti-plasma or B- cell) therapy, whereas 4 of 8 patients without an identifiable clone or mIg responded to anti-plasma cell therapy. At 60 months, the overall cumulative incidence of kidney failure requiring dialysis or death was 31.1% (7.9% to 48.5%). Four patients underwent kidney transplantation and three with transplant biopsies exhibited recurrent disease.</p><p><strong>Limitations: </strong>Retrospective, single-center study, non-standardized hematologic workup and management.</p><p><strong>Conclusions: </strong>Nearly 75% of PGNMID-IgG1 cases >50 years of age have a clonal population detected and nearly a quarter have CLL/SLL. Response to anti-B-cell therapy may be greater in those with an identifiable clone or mIg. These data may inform treatment strategies for people with PGNMID-IgG1.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative Management of Non-HLA Antibody and NK Cell-Mediated Rejection After Kidney Transplantation With Imlifidase: A Case Report. 应用Imlifidase治疗肾移植术后非hla抗体和NK细胞介导的排斥反应1例。
IF 9.4 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-11-02 DOI: 10.1053/j.ajkd.2026.06.035
Florent Von Tokarski, Marion Rabant, Valentin Goutaudier, Dany Anglicheau, Lionel Couzi, Maryvonnick Carmagnat, Emilie Lebraud, Anaïs Certain, Jessy Dagobert, Ramia Benhamou, Eva Languille-Llitjos, Alexandre Loupy, Jean-Luc Taupin, Florence Runyo, Alexandre Hertig, Arwa Jalal Eddine
{"title":"Innovative Management of Non-HLA Antibody and NK Cell-Mediated Rejection After Kidney Transplantation With Imlifidase: A Case Report.","authors":"Florent Von Tokarski, Marion Rabant, Valentin Goutaudier, Dany Anglicheau, Lionel Couzi, Maryvonnick Carmagnat, Emilie Lebraud, Anaïs Certain, Jessy Dagobert, Ramia Benhamou, Eva Languille-Llitjos, Alexandre Loupy, Jean-Luc Taupin, Florence Runyo, Alexandre Hertig, Arwa Jalal Eddine","doi":"10.1053/j.ajkd.2026.06.035","DOIUrl":"https://doi.org/10.1053/j.ajkd.2026.06.035","url":null,"abstract":"<p><p>A highly sensitized patient received a kidney transplant (KT) following imlifidase induction: we report an innovative diagnostic and therapeutic strategy for rejection management. On day 20 post-KT, the patient developed acute kidney injury, with donor-derived cell-free DNA (dd-cfDNA) increasing to 1.93%. Histology revealed isolated glomerulitis (g1) with C4d(2+) deposits along peritubular capillaries. Steroids and plasma exchanges were administered for suspected antibody-mediated rejection (AMR), despite no rebound of donor-specific anti-HLA antibodies (DSAs). Non-HLA anti-endothelial cell antibodies were positive, confirming AMR according to Banff 2022. Transcriptomic analysis showed overexpression of complement pathway-associated transcripts. C5 inhibition failed as serum creatinine further increased along with dd-cfDNA (3.96%). A second biopsy confirmed active AMR with increased expression of NK-related transcripts, leading to anti-CD38 treatment (daratumumab). At 6 months post-KT, the condition was controlled with stable creatinine at 20.4 μg/mL, dd-cfDNA decreased to 0.1%, microvascular inflammation resolved, non-HLA anti-endothelial cell antibodies became undetectable, still without HLA DSA rebound. Daratumumab is ongoing. Integrating dd-cfDNA, transcriptomic biopsy analysis, and non-HLA antibody assessment may optimize the management of highly sensitized KT recipients following imlifidase induction. However, long-term efficacy remains to be confirmed.</p>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":" ","pages":""},"PeriodicalIF":9.4,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书